Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases
NCT04832204Phase 2Unknown
- Sponsor
- Beijing Hospital
- Start
- Mar 2021
- Primary completion
- Apr 2023
- Modality
- Immune Checkpoint Inhibitors, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of Rivoceranib, camrelizumab in solid tumor, sponsored by Beijing Hospital. Status: unknown.
02
Drugs
Rivoceranibcamrelizumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT04832204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04832204.